Bayer and Janssen’s Xarelto shows promising results in reducing blood clot recurrence
Check out results of the late-breaking blood thinner clinical trial of Rivaroxaban, Bayer & Janssen’s oral blood thinner for deep vein thrombosis treatment.
Bayer AG and Janssen Pharmaceuticals, two giants in the pharmaceutical industry, have announced significant findings from their EINSTEIN CHOICE clinical trial, showcasing the effectiveness of Xarelto (rivaroxaban), an oral blood thinner, in substantially reducing the risk of recurrent life-threatening blood clots in vein, known as venous thromboembolism (VTE). Breakthrough in VTE Management The late-breaking study […]